Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Blackhawk Growth Corp C.BLR

Alternate Symbol(s):  C.BLR.W | BLRZF

Blackhawk Growth Corp. is a Canada-based investment holding company. The Company invests in equity and debt instruments of companies to generate positive returns for shareholders. It focuses on investing in multiple companies across a variety of sectors across North America. The Company has focused its investments on the health, cannabis and cannabidiol (CBD) industries, in both Canada and the United States.


CSE:BLR - Post by User

Post by bveilleuon Sep 16, 2021 11:41am
101 Views
Post# 33868554

MindBio Therapeutics to Commercialize Intellectual Property

MindBio Therapeutics to Commercialize Intellectual Property

Vancouver, British Columbia – TheNewswire - September 16, 2021 – Blackhawk Growth Corp. (CSE:BLR); (CNSX:BLR.CN); (OTC:BLRZF); (Frankfurt:0JJ) (the “Company” or “Blackhawk”) is pleased to provide an update on MindBio Therapeutics Pty Ltd. (“MindBio Therapeutics”), a clinical stage drug development company conducting research into microdosing and medicinal use of psychedelic medicine. 

 

MindBio Therapeutics plans to commercialize the intellectual property generated from the University of Auckland’s clinical trial in psychedelic assisted therapy in advanced-stage cancer patients. The administration of high-dose psychedelic compounds have shown clinically significant benefits in the treatment of psychological distress in advanced cancer patients. However, psychedelics at high doses can vividly alter perceptions; an experience that poses challenges in this vulnerable population. ‘Microdosing’ – repeated administration of psychedelics in low doses does not alter perceptions but may offer similar benefit in reducing anxiety, depression and existential distress. This study will evaluate the feasibility of conducting a randomised controlled trial comparing psychedelic-microdose assisted in people who have advanced cancer and anxiety or depression.

 

Participants will be randomised to receive psychotherapy alongside doses of either an LSD microdose or placebo. The feasibility, acceptability, safety and potential psychological benefits of this intervention will be assessed. The findings will inform the development of a larger trial and provide initial indication of potential benefits of psychedelic microdosing in advanced cancer.

   

About Blackhawk Growth

 

Blackhawk is an investment holding looking to create substantial value for its shareholders through the acquisition and development of high growth companies. It has focused its investments in the health, cannabis and cannabidiol industries in both Canada and the United States. Its portfolio of companies includes Sac Pharma, LeichtMind Clinics, Noble Hemp, Spaced Food, NuWave Foods, and MindBio Therapeutics. Blackhawk continues to bring its investments to cash flow and is growing at an exceeding pace.

The Company diligently posts updates through videos from the official company YouTube channel https://www.youtube.com/channel/UCs4f2tt3yAvOGhNLjgNOy-A  

Please join the conversation on our Blackhawk group supporter’s telegram group at https://t.me/Blackhawkgrowthcorp and visit us online at https://www.blackhawkgrowth.com.

For further information please contact:

Frederick Pels, Chief Executive Officer

(403)-991-7737

fred@blackhawkgrowth.com

<< Previous
Bullboard Posts
Next >>